Osteoporosis medication and reduced mortality risk in elderly women and men

Center, JR; Bliuc, D; Nguyen, ND; Nguyen, TV; Eisman, JA

Osteoporosis medication and reduced mortality risk in elderly women and men

Center, JR Bliuc, D Nguyen, ND Nguyen, TV

Eisman, JA

Permalink

Publication Type:: Journal Article
Citation:: Journal of Clinical Endocrinology and Metabolism, 2011, 96 (4), pp. 1006 - 1014
Issue Date:: 2011-04-01

Closed Access

	Filename	Description	Size
	2013005859OK.pdf		390.62 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Center, JR	en_US
dc.contributor.author	Bliuc, D	en_US
dc.contributor.author	Nguyen, ND	en_US
dc.contributor.author	Nguyen, TV https://orcid.org/0000-0002-3246-6281	en_US
dc.contributor.author	Eisman, JA	en_US
dc.date.issued	2011-04-01	en_US
dc.identifier.citation	Journal of Clinical Endocrinology and Metabolism, 2011, 96 (4), pp. 1006 - 1014	en_US
dc.identifier.issn	0021-972X	en_US
dc.identifier.uri	http://hdl.handle.net/10453/28731
dc.description.abstract	Context: Osteoporotic fractures are associated with premature mortality. Antiresorptive treatment reduces refracture but mortality reduction is unclear. Objective: The objective of the study was to examine the effect of osteoporosis treatment [bisphosphonates (BP), hormone therapy (HT), and calcium ± vitamin D only (CaD)] on mortality risk. Design: This was a prospective cohort study (April 1989 to May 2007). Setting: The study was conducted with community-dwelling elderly (aged 60+ yr) subjects in Dubbo, a semiurban city, Australia. Subjects: Subjects included 1223 and 819 women and men in the Dubbo Osteoporosis Epidemiology Study. Main Outcome Measure: Mortality according to treatment group was recorded. Results: There were 325 (BP, n = 106; HT, n = 77; CaD, n = 142) women and 37 men (BP, n = 15; CaD, n=22) on treatment. In women, mortality rates were lower with BP 0.8/100 person-years (0.4, 1.4) and HT 1.2/100 person-years (0.7, 2.1) but not CaD 3.2/100 person-years (2.5, 4.1) vs. no treatment 3.5/100 person-years (3.1, 3.8). Accounting for age, fracture occurrence, comorbidities, quadriceps strength, and bone mineral density, mortality risk remained lower for women on BP [hazard ratio (HR) 0.3 (0.2, 0.6)] but not HT [HR 0.8 (0.4, 1.8)]. For 429 women with fractures, mortality risk was still reduced in the BP group [adjusted HR 0.3 (0.2, 0.7)], not accounted for by a reduction in subsequent fractures. In men, lower mortality rates were observed with BP but not CaD [BP 1.0/100 person-years (0.3, 3.9) and CaD 3.1/100 person-years (1.5, 6.6) vs. no treatment 4.3/100 person-years (3.9, 4.8)]. After adjustment, mortality was similar, although not significant [HR 0.5 (0.1, 2.0)]. Conclusions: Osteoporosis therapy appears to reduce mortality risk in women and possibly men. Copyright © 2011 by The Endocrine Society.	en_US
dc.relation.ispartof	Journal of Clinical Endocrinology and Metabolism	en_US
dc.relation.isbasedon	10.1210/jc.2010-2730	en_US
dc.subject.classification	Endocrinology & Metabolism	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Osteoporosis	en_US
dc.subject.mesh	Alendronate	en_US
dc.subject.mesh	Etidronic Acid	en_US
dc.subject.mesh	Mortality	en_US
dc.subject.mesh	Risk Factors	en_US
dc.subject.mesh	Cohort Studies	en_US
dc.subject.mesh	Follow-Up Studies	en_US
dc.subject.mesh	Comorbidity	en_US
dc.subject.mesh	Algorithms	en_US
dc.subject.mesh	Aged	en_US
dc.subject.mesh	Aged, 80 and over	en_US
dc.subject.mesh	Middle Aged	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Male	en_US
dc.subject.mesh	Bone Density Conservation Agents	en_US
dc.subject.mesh	Osteoporotic Fractures	en_US
dc.subject.mesh	Risedronic Acid	en_US
dc.title	Osteoporosis medication and reduced mortality risk in elderly women and men	en_US
dc.type	Journal Article
utslib.citation.volume	4	en_US
utslib.citation.volume	96	en_US
utslib.for	1103 Clinical Sciences	en_US
utslib.for	0903 Biomedical Engineering	en_US
utslib.for	1114 Paediatrics and Reproductive Medicine	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	closed_access
pubs.issue	4	en_US
pubs.publication-status	Published	en_US
pubs.volume	96	en_US

Abstract:

Context: Osteoporotic fractures are associated with premature mortality. Antiresorptive treatment reduces refracture but mortality reduction is unclear. Objective: The objective of the study was to examine the effect of osteoporosis treatment [bisphosphonates (BP), hormone therapy (HT), and calcium ± vitamin D only (CaD)] on mortality risk. Design: This was a prospective cohort study (April 1989 to May 2007). Setting: The study was conducted with community-dwelling elderly (aged 60+ yr) subjects in Dubbo, a semiurban city, Australia. Subjects: Subjects included 1223 and 819 women and men in the Dubbo Osteoporosis Epidemiology Study. Main Outcome Measure: Mortality according to treatment group was recorded. Results: There were 325 (BP, n = 106; HT, n = 77; CaD, n = 142) women and 37 men (BP, n = 15; CaD, n=22) on treatment. In women, mortality rates were lower with BP 0.8/100 person-years (0.4, 1.4) and HT 1.2/100 person-years (0.7, 2.1) but not CaD 3.2/100 person-years (2.5, 4.1) vs. no treatment 3.5/100 person-years (3.1, 3.8). Accounting for age, fracture occurrence, comorbidities, quadriceps strength, and bone mineral density, mortality risk remained lower for women on BP [hazard ratio (HR) 0.3 (0.2, 0.6)] but not HT [HR 0.8 (0.4, 1.8)]. For 429 women with fractures, mortality risk was still reduced in the BP group [adjusted HR 0.3 (0.2, 0.7)], not accounted for by a reduction in subsequent fractures. In men, lower mortality rates were observed with BP but not CaD [BP 1.0/100 person-years (0.3, 3.9) and CaD 3.1/100 person-years (1.5, 6.6) vs. no treatment 4.3/100 person-years (3.9, 4.8)]. After adjustment, mortality was similar, although not significant [HR 0.5 (0.1, 2.0)]. Conclusions: Osteoporosis therapy appears to reduce mortality risk in women and possibly men. Copyright © 2011 by The Endocrine Society.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/28731